C. Difficile

Tonight, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product, intended to prevent recurrent C difficile infection in adults.

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

The closely watched therapeutic candidate led to long-term responses in 90% of patients who benefited from the therapy.

November is Clostridioides difficile (C diff) awareness month. The Peggy Lillis Foundation hopes to use the month to increase the public’s awareness of the dangers of the infection.

Extending antimicrobial stewardship programs to transition of care and discharge may prove beneficial to reduce unnecessary antibiotic use.

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.

A European panel of experts endorsed the FDA’s recommendations.

Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).

Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.

A fecal microbiota transplant (FMT) trial was halted early due to clear evidence the treatment was superior to placebo.

The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.

Bifidobacterium and Bacteroides in the gut microbiome are important to vaccine responsiveness and could be used in vaccine adjuvants in the future, a recent review shows.

Experts review treatment options for first, second and recurring episodes of Clostridioides difficile infection.

A gastroenterologist reviews long-term impact of dysbiosis and C. difficile infection (CDI).

Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.

Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.

A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).

Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).

Dr. Chopra shares multipronged approach to reducing C. difficile infection (CDI) and the role of antimicrobial stewardship.

Drs. Abraham, Chopra and Feuerstadt discuss importance of timely referral and diagnostic methods to discern C. difficile infection (CDI).

Drs Lodise and Feuerstadt discuss risk factors for C. difficile infection (CDI).

A gastroenterologist, Dr. Paul Feuerstadt, provides an overview of C. difficile infection (CDI) and vegetative and spore phases of CDI.

An FDA advisory committee will meet on September 22, 2022 to decide whether to approve a biologics license application (BLA) for Ferring’s recurrent C difficile biotherapeutic, RBX2660.

Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.